Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H28N2 |
| Molecular Weight | 284.439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCN1C2=C(CCCCCC2)C3=C1C=CC=C3
InChI
InChIKey=PLIGPBGDXASWPX-UHFFFAOYSA-N
InChI=1S/C19H28N2/c1-20(2)14-9-15-21-18-12-6-4-3-5-10-16(18)17-11-7-8-13-19(17)21/h7-8,11,13H,3-6,9-10,12,14-15H2,1-2H3
| Molecular Formula | C19H28N2 |
| Molecular Weight | 284.439 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Getting the balance right: Established and emerging therapies for major depressive disorders. | 2010-09-07 |
|
| Research on antidepressants in India. | 2010-01 |
|
| The evolution of Indian psychiatric research: An examination of the early decades of the Indian Journal of Psychiatry. | 2010-01 |
|
| Contribution of sleep research to the development of new antidepressants. | 2005 |
|
| Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies. | 2002-08 |
|
| 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. | 2002-04 |
|
| Prenatal exposure of rats to antidepressants enhances agonist affinity of brain dopamine receptors and dopamine-mediated behaviour. | 1985-10-22 |
|
| Changes in amphetamine-induced anorexia and stereotypy during chronic treatment with antidepressant drugs. | 1984-03-02 |
|
| Effects of chronic administration of antidepressant drugs on aggressive behavior induced by clonidine in mice. | 1980-08 |
|
| Chronic treatment with antidepressant drugs: potentiation of apomorphine-induced aggressive behaviour in rats. | 1979-08 |
|
| Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs. | 1979 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5416820
15 mg three times a day
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:43:24 GMT 2025
by
admin
on
Mon Mar 31 21:43:24 GMT 2025
|
| Record UNII |
69U0IKR8FP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
N06AA13
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
||
|
WHO-VATC |
QN06AA13
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5979
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | RxNorm | ||
|
D007488
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
100000083123
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
C166921
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
226-933-5
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
5560-72-5
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
IPRINDOLE
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
169449
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
DB13496
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
DTXSID80204145
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
1478
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
1854
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
21722
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
m6389
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB08279MIG
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL126224
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY | |||
|
69U0IKR8FP
Created by
admin on Mon Mar 31 21:43:24 GMT 2025 , Edited by admin on Mon Mar 31 21:43:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |